Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $20.40

Keros Therapeutics, Inc. (NASDAQ:KROS) has received an average rating of “Hold” from the eight research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $20.40.

Several equities analysts have recently commented on the company. Wells Fargo & Company lowered their price objective on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th.

Institutional Investors Weigh In On Keros Therapeutics

Several large investors have recently made changes to their positions in KROS. AQR Capital Management LLC bought a new stake in shares of Keros Therapeutics in the first quarter worth about $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Keros Therapeutics by 15.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after acquiring an additional 2,982 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares during the last quarter. Creative Planning increased its stake in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after acquiring an additional 6,948 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Keros Therapeutics by 16.0% during the second quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after acquiring an additional 7,146 shares during the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $10.55 on Wednesday. The company has a market capitalization of $208.78 million, a PE ratio of -3.50 and a beta of 0.94. The business’s fifty day moving average is $11.38 and its 200 day moving average is $15.34. Keros Therapeutics has a fifty-two week low of $9.79 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The company had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. On average, sell-side analysts forecast that Keros Therapeutics will post -5.62 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.